गोल्डलाईन फार्मास्युटिकल शेअर किंमत

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prashant Shrikrishna Karkare

• बीएसई इंडिया
• 1 आठवड्यापूर्वी

मे. ची अपॉईंटमेंट. Avinash Prakash Gandhewar, Practicing Company Secretaries, Membership No. FCS 11197 as Secretarial Auditor of the Company for the FY 2025-26.

• बीएसई इंडिया
• 3 आठवडे 1 दिवसापूर्वी

मोठे कॉर्पोरेट म्हणून ओळखलेल्या संस्थेद्वारे केलेल्या प्रारंभिक प्रकटीकरणाचा फॉरमॅट. Sr. No. Particulars Details 1Name of CompanyGoldline Pharmaceutical Ltd 2CIN NO.U51397MH2004PLC147806 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 9.16 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: RUCHI SANKET MODI Designation: COMPANY SECRETARY EmailId: GOLDLINEPHARMACEUTICALSLTD@GMAIL.COM Name of the Chief Financial Officer: DIPTI SHARAD BHUSARI Designation: CHIEF FINANCIAL OFFICER EmailId: GOLDLINEPHARMACEUTICALSLTD@GMAIL.COM Date: 24/06/2026 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. त्यामुळे, LC म्हणून ओळखली जाणारी संस्था, फायनान्शियल वर्षासाठी त्यांच्या प्रारंभिक प्रकटीकरणात, डेब्ट मार्केटद्वारे अनिवार्य लोन घेण्याच्या बाबतीत ज्या स्टॉक एक्सचेंजला दंड भरावा लागेल.

• बीएसई इंडिया
• 1 महिना 1 आठवड्यापूर्वी